



Responding to the FDA & Basics of Remediation

“Tales from the Dark Side”




5 W S CONSULTING
For the FDA Regulated Industry

Setting the Tone



**You just received an FDA-483
with Data Integrity
Observations**



*“Records were Fabricated, Altered,
Concealed or Missing.”*

Now what??

April 18, 2017 PTEA Conference 2

Overview

Tales from the Dark Side



- Response Timing
- Response Content
 - Follow-Up on Response
 - FDA’s Steps/Actions
 - Requesting a Meeting
 - Remediation Choices
 - Remediation Reminders
 - Closing Summary

April 18, 2017 PTEA Conference 3

Response Timing

April 18, 2017 PTEA Conference 4

Response - Timing

You have 15 working days for initial response to 483:

- **Do** have consultant/advisor with FDA compliance experience review response
- **Don't** send it to consultant/advisor last minute *(Multiple revisions may be required)*

April 18, 2017 PTEA Conference 5

Response Timing

NOTE:
This is only a preliminary response!

April 18, 2017 PTEA Conference 6

Response Content

April 18, 2017 PTEA Conference 7

Response Content

- **Be positive and professional!**
 - **DO NOT** denigrate the FDA investigator.
 - **Acknowledge** the finding.
 - **Give explanations, not excuses.**
- **Give evidence as attachments**
- **Use professional language and grammar**

April 18, 2017 PTEA Conference 8

Response Content

- **Introduction/Summary**
- **FDA Finding, followed by:**
 - **Explanation of facts about finding**
 - **Company practices, SOPs, results of preliminary investigations**
 - **Proposed actions/Risk assessment based on preliminary investigations and impact assessment**
- **Table**
- **Exhibits**

April 18, 2017 PTEA Conference 9


Response Content

Example of table:


CAPA Plan				
Observation	CAPA	Responsible Person(s) or Departments	Proposed Completion Date	Actual Completion Date

April 18, 2017 PTEA Conference 10

Response Content



- Include timeframe for sending follow-up to response to FDA
- DO NOT tell FDA your remediation is complete if it isn't.
- CAPAs should be global/systematic



April 18, 2017 PTEA Conference 11

Follow-up to Response

April 18, 2017 PTEA Conference 12

Follow-up to Response

What should a follow-up look like?



April 18, 2017 PTEA Conference 13

Follow-up to Response

- Mimic initial response format
- Follow-up by timeline specified in initial response
- Be clear in steps taken between follow-ups

COMPLETED

April 18, 2017 PTEA Conference 14


FDAs Steps/Actions



April 18, 2017 PTEA Conference 15

FDA's Steps/Actions

When should you hear back from FDA?



April 18, 2017 PTEA Conference 16

FDA's Steps/Actions

Decision

- How necessary and available is your product?
- Opportunity to make global changes
- Other plants?

Research/Discussion

Review of Response/EIR

Establishment Inspection Report (EIR)

Audit/FDA 483

April 18, 2017 PTEA Conference 17

Warning Letter Excerpt:

If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER's Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b) and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.

"If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that FDA can work with you on the most effective way to bring your operations into compliance with the law..."

April 18, 2017 PTEA Conference 18

Requesting a Meeting

April 18, 2017 PTEA Conference 19

Requesting a meeting

When should you request a meeting with FDA?



April 18, 2017 PTEA Conference 20

Requesting a Meeting

A meeting is not always the best option, but might help to:

- Meet the face
- To provide updates on commitments made
- To discuss short supply Impact if plant is shut down
- Clarify FDA expectations

April 18, 2017 PTEA Conference 21

Requesting a Meeting

Preparing for meetings:

- **Detailed agenda with:**
 - Attendees/Titles
 - Topics
 - Offer Dates & Times
 - Limit it to 1 to 2 hours
 - Send in advance



Keep to the agenda and timeline!!

April 18, 2017 PTEA Conference 22


Remediation

April 18, 2017 PTEA Conference 23

Remediation: Components

- Investigation and risk assessment
- Retroactive data review
- Further testing

- Communication with customers & vendors
- Recalls
- Personnel move/remove
- Other CAPAs



- SOP review, rewriting and creation
- Training
- Verification of training effectiveness

April 18, 2017 PTEA Conference 24

Remediation - Choices

Who will perform remediation?

1. Consultants
2. DIY (Do It Yourself)
3. Combination of both

April 18, 2017 PTEA Conference 25

Remediation - Choice #1

Select Consultants if:

- You don't have the people
- You don't have the expertise
- FDA strongly suggests it
- Your customer requires it

April 18, 2017 PTEA Conference 26

Warning Letter Excerpt:

Data Integrity Remediation

Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. We strongly recommend that you retain a qualified consultant to assist in your remediation.

“Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. We **strongly recommend** that you retain a qualified consultant to assist in your remediation.”

April 18, 2017 PTEA Conference 27

Remediation - Choice #1

Considerations:

- Contract requirements
- Lack of ownership
- Can be costly
- Not always a guarantee of success

April 18, 2017 PTEA Conference 28


Remediation - Choice #2

DIY if:


- You have enough people
- You have enough expertise
- You have the choice

Benefit – Ownership

April 18, 2017 PTEA Conference 29

Remediation - Choice #3 

Use consultants for some things:

- CAPA and plan help/review
- Help with retrospective review
- Progress audits 

NOTE: Use appropriate expertise and be prepared to share CV of consultant

April 18, 2017 PTEA Conference 30

Remember...

- Don't tell FDA you're ready until you've verified.
- Make changes globally
Verify globally!
- Consider transparency

COMPLETED



April 18, 2017 PTEA Conference 31

Remediation

As you go through remediation...

- Integrity is about perception
- Each auditor is different
- Kaizen (*continuous improvement*)

April 18, 2017 PTEA Conference 32

In Closing...

April 18, 2017 PTEA Conference 33

In Summary:

FDA Responses:

- Be positive and professional
- Provide explanations, not excuses
- Don't try to fix everything before the initial response

April 18, 2017 PTEA Conference 34

In Summary:

Remediation:

- Choose your level of involvement (if you can)
- Make changes globally
- Don't tell the FDA you're ready until you have verified.

April 18, 2017 PTEA Conference 35

Thank you!

Jose Hernandez

**Former FDA Investigator
And Compliance Officer**

Integrity and Quality Systems SME

804-402-2237

5wsconsultingllc@gmail.com



April 18, 2017 PTEA Conference 36
